Background
Traditional therapeutic antibody discovery remains a labor-intensive, project-based workflow. While de novo computational approaches offer speed, they often lack biological validation, increasing downstream risks. To maximize discovery efficiency, throughput, and lead quality, Biocytogen launched the RenSuper™ platform, establishing a closed-loop engine that integrates in vivo immune repertoires, Al-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure.
Methods
RenSuper Workstation™ transforms antibody discovery into a searchable and programmable system with off-the-shelf access to an experimentally validated library covering over 1,000 targets. Proprietary Al models trained on >IOO million biologically pre-validated in vivo sequences (derived from RenMice® platforms) perform one-click target-to-lead candidate selection. Candidates are evaluated for binding, affinity, specificity, and developability, and seamlessly assembled into monoclonal, bispecific (utilizing RenLite® common light chain technology), and VHH formats. High-confidence leads are then handed off to the RenSuper High-Throughput Automation Center. Operating 24/7, this fully automated infrastructure executes the entire production workflow—including bacterial inoculation, plasmid extraction, transfection, fed-batch cultivation, and purification
Results
Combining in vivo immune diversity with Al-driven selection and industrial automation can significantly increase the scale, quality and speed of discovery. For instance, using Biocytogen's RenNano® fully human HCAb platform, Al-driven candidate screening achieves a median positive hit rate of 46% (with peak rates reaching 98%), delivering an 82% success rate for the expression of high-purity antibodies ≥90%). The automation centre can process up to 800 samples per day (over 5,000 per week), achieving average yields of 50—100 mg per sample and drastically shortening the time taken to transition from molecular design to functional evaluation.
Conclusion
RenSuper Workstation™ establishes an intelligence-native, target-to-lead ecosystem. By unifying biologically validated in vivo immune repertoires, Al-driven precision selection, and automated high-throughput manufacturing, RenSuper provides a highly efficient, scalable, and de-risked paradigm for global biologics innovation.
